<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="87326">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01880151</url>
  </required_header>
  <id_info>
    <org_study_id>C12-71</org_study_id>
    <secondary_id>2013-A00344-41</secondary_id>
    <nct_id>NCT01880151</nct_id>
  </id_info>
  <brief_title>Neuroelectrical Biomarkers for Alzheimer's Disease Stages</brief_title>
  <acronym>ESTIMATE</acronym>
  <official_title>NEw approacheS for The dIagnosis of AlzeiMer's diseAse Through neuroElectrical Changes in the Brain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent diagnostic criteria for Alzheimer's disease (AD) recognize an extended spectrum of AD
      stages as part of the disease, including a preclinical stage. This underscores the
      importance of early prognosis of AD when it is still possible to influence the course of the
      disorder. The investigators propose a comprehensive project which will target the
      data-driven modeling of the disease development. This goal will be achieved by creating and
      validating a battery of new sensitive biomarkers for clinical evaluation and prediction of
      AD in individuals. The AD-related brain changes will be assessed by noninvasive functional
      EEG measured during an episodic memory task in subjects at different stages of AD, as well
      as in healthy controls. The novel functional biomarkers will be extracted using a rigorous
      multistage selection procedure involving advanced methods for feature extraction, as well as
      statistics and classification for optimal selection. The ESTIMATE project will serve as a
      first step in an extensive array of research procedures which will enable the early clinical
      identification of Alzheimer's disease in elderly individuals who could then take advantage
      of preventive pharmaceutical therapies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Frequency band charactersitics of the electrophysiological brain response</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Prodromal AD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Presence of memory impairment Absence of impairment in activities of daily life EEG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild AD dementia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Presence of memory impairment Presence of impairment in activities of daily life EEG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Absence of memory impairment Absence of impairment in activities of daily life Absence of known neurological conditions EEG</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EEG</intervention_name>
    <description>EEG recorded during a resting condition and during an episodic memory task condition</description>
    <arm_group_label>Prodromal AD</arm_group_label>
    <arm_group_label>Mild AD dementia</arm_group_label>
    <arm_group_label>Healthy control group</arm_group_label>
    <other_name>Electroencephalography</other_name>
    <other_name>Electrical Geodesics Incorporated</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 70-85 years old

          -  Presence of memory impairment

          -  Completed educational level: middle school

          -  Visual and auditory acuity: normal or corrected-to-normal

        Exclusion Criteria:

          -  Monogenic AD

          -  Presence of a neurological disorder

          -  Stroke that has occurred in the last three months

          -  Prohibited medications

          -  Residence in skilled nursing facility

          -  Illiteracy, is unable to count or to read

          -  Claustrophobia
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Dubois, PhD,MD,Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Memory and Alzheimer's Disease, Pitie-Salpetriere Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hovagim Bakardjian, Ph.D.</last_name>
    <email>h.bakardjian-ihu@icm-institute.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Memory and Alzheimer's Disease, Pitie-Salpetriere Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hovagim Bakardjian, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 7, 2013</lastchanged_date>
  <firstreceived_date>June 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <keyword>Dementia</keyword>
  <keyword>Prodromal</keyword>
  <keyword>EEG</keyword>
  <keyword>ERP</keyword>
  <keyword>Biomarkers</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
